38.27 USD
-0.28 (-0.73%)
38.9 USD
+0.63 (+1.65%)
HRMY gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. HRMY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. HRMY is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make HRMY suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
HRMY had positive earnings in the past year.
HRMY had a positive operating cash flow in the past year.
HRMY had positive earnings in 4 of the past 5 years.
Of the past 5 years HRMY 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of HRMY (15.37%) is better than 95.26% of its industry peers.
With an excellent Return On Equity value of 22.23%, HRMY belongs to the best of the industry, outperforming 92.63% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 17.20%, HRMY belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for HRMY is significantly above the industry average of 12.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROIC | 17.2% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
1.3 Margins
The Profit Margin of HRMY (22.48%) is better than 91.58% of its industry peers.
HRMY's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 27.32%, HRMY belongs to the top of the industry, outperforming 93.16% of the companies in the same industry.
In the last couple of years the Operating Margin of HRMY has declined.
Looking at the Gross Margin, with a value of 77.70%, HRMY belongs to the top of the industry, outperforming 83.16% of the companies in the same industry.
In the last couple of years the Gross Margin of HRMY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% |
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
HRMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, HRMY has more shares outstanding
Compared to 5 years ago, HRMY has less shares outstanding
HRMY has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.64 indicates that HRMY is not in any danger for bankruptcy at the moment.
HRMY has a better Altman-Z score (5.64) than 75.26% of its industry peers.
The Debt to FCF ratio of HRMY is 0.57, which is an excellent value as it means it would take HRMY, only 0.57 years of fcf income to pay off all of its debts.
HRMY has a better Debt to FCF ratio (0.57) than 96.84% of its industry peers.
HRMY has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of HRMY (0.18) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Altman-Z | 5.64 |
ROIC/WACC1.81
WACC9.49%
2.3 Liquidity
HRMY has a Current Ratio of 3.75. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of HRMY (3.75) is comparable to the rest of the industry.
HRMY has a Quick Ratio of 3.72. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.72, HRMY perfoms like the industry average, outperforming 58.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 |
3. Growth
3.1 Past
HRMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.71%, which is quite impressive.
The Earnings Per Share has been growing by 44.61% on average over the past years. This is a very strong growth
The Revenue has grown by 21.13% in the past year. This is a very strong growth!
HRMY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 160.13% yearly.
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
3.2 Future
The Earnings Per Share is expected to grow by 35.10% on average over the next years. This is a very strong growth
Based on estimates for the next years, HRMY will show a quite strong growth in Revenue. The Revenue will grow by 14.79% on average per year.
EPS Next Y29.83%
EPS Next 2Y29.75%
EPS Next 3Y25%
EPS Next 5Y35.1%
Revenue Next Year20.8%
Revenue Next 2Y18.45%
Revenue Next 3Y16.54%
Revenue Next 5Y14.79%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
HRMY is valuated correctly with a Price/Earnings ratio of 12.03.
Based on the Price/Earnings ratio, HRMY is valued cheaply inside the industry as 88.42% of the companies are valued more expensively.
HRMY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.25.
HRMY is valuated reasonably with a Price/Forward Earnings ratio of 9.06.
Based on the Price/Forward Earnings ratio, HRMY is valued cheaply inside the industry as 89.47% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.98, HRMY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.03 | ||
| Fwd PE | 9.06 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 94.21% of the companies listed in the same industry.
HRMY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HRMY is cheaper than 95.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.42 | ||
| EV/EBITDA | 6.78 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HRMY has an outstanding profitability rating, which may justify a higher PE ratio.
HRMY's earnings are expected to grow with 25.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y29.75%
EPS Next 3Y25%
5. Dividend
5.1 Amount
HRMY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
38.27
-0.28 (-0.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners85.16%
Inst Owner Change2.11%
Ins Owners1.63%
Ins Owner Change-61.8%
Market Cap2.20B
Revenue(TTM)825.94M
Net Income(TTM)185.68M
Analysts78.82
Price Target47.11 (23.1%)
Short Float %8.89%
Short Ratio5.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.77%
Min EPS beat(2)-11.17%
Max EPS beat(2)1.62%
EPS beat(4)3
Avg EPS beat(4)8.56%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)57.65%
EPS beat(12)9
Avg EPS beat(12)44.35%
EPS beat(16)12
Avg EPS beat(16)96.55%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)4.96%
Revenue beat(8)1
Avg Revenue beat(8)-1%
Revenue beat(12)3
Avg Revenue beat(12)-0.86%
Revenue beat(16)5
Avg Revenue beat(16)-0.67%
PT rev (1m)0%
PT rev (3m)3.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.87%
EPS NY rev (1m)0%
EPS NY rev (3m)2.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.03 | ||
| Fwd PE | 9.06 | ||
| P/S | 2.67 | ||
| P/FCF | 7.42 | ||
| P/OCF | 7.41 | ||
| P/B | 2.64 | ||
| P/tB | 2.98 | ||
| EV/EBITDA | 6.78 |
EPS(TTM)3.18
EY8.31%
EPS(NY)4.23
Fwd EY11.04%
FCF(TTM)5.15
FCFY13.47%
OCF(TTM)5.17
OCFY13.5%
SpS14.34
BVpS14.5
TBVpS12.84
PEG (NY)0.4
PEG (5Y)N/A
Graham Number32.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROCE | 22.91% | ||
| ROIC | 17.2% | ||
| ROICexc | 54.26% | ||
| ROICexgc | 78.12% | ||
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% | ||
| FCFM | 35.95% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexgc growth 3Y-76.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Debt/EBITDA | 0.6 | ||
| Cap/Depr | 3% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 14.73 | ||
| Cash Conversion | 119.28% | ||
| Profit Quality | 159.9% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 | ||
| Altman-Z | 5.64 |
F-Score6
WACC9.49%
ROIC/WACC1.81
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
EPS Next Y29.83%
EPS Next 2Y29.75%
EPS Next 3Y25%
EPS Next 5Y35.1%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
Revenue Next Year20.8%
Revenue Next 2Y18.45%
Revenue Next 3Y16.54%
Revenue Next 5Y14.79%
EBIT growth 1Y17.58%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year37.1%
EBIT Next 3Y27.64%
EBIT Next 5Y23.54%
FCF growth 1Y75.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.68%
OCF growth 3Y30.64%
OCF growth 5YN/A
HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ
Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a fundamental rating of 8 / 10 to HRMY.
What is the valuation status of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?
ChartMill assigns a valuation rating of 9 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.
Can you provide the profitability details for HARMONY BIOSCIENCES HOLDINGS?
HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.
What are the PE and PB ratios of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?
The Price/Earnings (PE) ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 12.03 and the Price/Book (PB) ratio is 2.64.
What is the earnings growth outlook for HARMONY BIOSCIENCES HOLDINGS?
The Earnings per Share (EPS) of HARMONY BIOSCIENCES HOLDINGS (HRMY) is expected to grow by 29.83% in the next year.